

# S John Weroha

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5808282/publications.pdf>

Version: 2024-02-01

47  
papers

3,062  
citations

304743

22  
h-index

243625

44  
g-index

47  
all docs

47  
docs citations

47  
times ranked

5583  
citing authors

#	ARTICLE	IF	CITATIONS
1	Senolytics improve physical function and increase lifespan in old age. <i>Nature Medicine</i> , 2018, 24, 1246-1256.	30.7	1,384
2	Tumorgrafts as <i>In Vivo</i> Surrogates for Women with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1288-1297.	7.0	168
3	The Insulin-Like Growth Factor System in Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2012, 41, 335-350.	3.2	165
4	IGF-1 Receptor Inhibitors in Clinical Trials—Early Lessons. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2008, 13, 471-483.	2.7	159
5	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. <i>Cancer Research</i> , 2017, 77, e62-e66.	0.9	92
6	Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1123-1132.	6.3	83
7	LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. <i>Cancer Cell</i> , 2017, 32, 310-323.e5.	16.8	80
8	In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016, 143, 379-388.	1.4	57
9	A microfluidic platform for cultivating ovarian cancer spheroids and testing their responses to chemotherapies. <i>Microsystems and Nanoengineering</i> , 2020, 6, 93.	7.0	56
10	Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. <i>Cancer</i> , 2020, 126, 894-907.	4.1	54
11	Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion. <i>Cancer Research</i> , 2017, 77, 6524-6537.	0.9	51
12	Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts. <i>Neoplasia</i> , 2017, 19, 628-636.	5.3	49
13	Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. <i>Nature Communications</i> , 2020, 11, 5173.	12.8	46
14	The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3397-3407.	7.0	45
15	Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer. <i>Scientific Reports</i> , 2019, 9, 11153.	3.3	44
16	LY2157299 Monohydrate, a TGF- $\beta$ 1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer. <i>Cancers</i> , 2018, 10, 260.	3.7	42
17	Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2021, 81, 4709-4722.	0.9	42
18	BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents. <i>Cancer Research</i> , 2019, 79, 5920-5929.	0.9	40

#	ARTICLE	IF	CITATIONS
19	Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. <i>Gynecologic Oncology</i> , 2017, 146, 64-68.	1.4	35
20	Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. <i>ESMO Open</i> , 2020, 5, e000926.	4.5	35
21	Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts. <i>Scientific Reports</i> , 2019, 9, 6314.	3.3	33
22	Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1101-1109.	2.5	26
23	Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer. <i>Cancer Research</i> , 2022, 82, 1038-1054.	0.9	26
24	Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. <i>Cell Reports Medicine</i> , 2021, 2, 100471.	6.5	26
25	Conventional Chemotherapy and Oncogenic Pathway Targeting in Ovarian Carcinosarcoma Using a Patient-Derived Tumorgraft. <i>PLoS ONE</i> , 2015, 10, e0126867.	2.5	24
26	Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes. <i>Oncotarget</i> , 2017, 8, 46891-46899.	1.8	22
27	ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer. <i>Nature Communications</i> , 2019, 10, 4632.	12.8	21
28	Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments. <i>Cancer Research</i> , 2021, 81, 3727-3737.	0.9	20
29	Characterization of a <i>RAD51C</i> -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. <i>NAR Cancer</i> , 2021, 3, zcab028.	3.1	20
30	Targeting an autocrine IL-6/SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma. <i>Oncogene</i> , 2020, 39, 6606-6618.	5.9	15
31	Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer. <i>Theranostics</i> , 2020, 10, 2095-2114.	10.0	15
32	GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma. <i>Cancer Research</i> , 2021, 81, 2995-3007.	0.9	15
33	Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing. <i>BMC Medical Genomics</i> , 2021, 14, 165.	1.5	10
34	Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting. <i>Scientific Reports</i> , 2021, 11, 8076.	3.3	9
35	Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer. <i>BMC Cancer</i> , 2016, 16, 814.	2.6	8
36	Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2022, 82, 307-319.	0.9	8

#	ARTICLE	IF	CITATIONS
37	Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma. <i>Cancers</i> , 2020, 12, 869.	3.7	7
38	Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A. <i>PLoS ONE</i> , 2019, 14, e0224564.	2.5	6
39	Investigation of factors affecting the efficacy of 3C23K, a human monoclonal antibody targeting MISIR. <i>Oncotarget</i> , 2017, 8, 85214-85223.	1.8	6
40	Non-gestational choriocarcinoma with hyperprogression on pembrolizumab: A case report and review of the literature. <i>Gynecologic Oncology Reports</i> , 2022, 39, 100923.	0.6	6
41	Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options. <i>PLoS ONE</i> , 2021, 16, e0245664.	2.5	5
42	Ureteral obstruction in cancer patients: a qualitative study. <i>Psycho-Oncology</i> , 2016, 25, 605-609.	2.3	3
43	High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas. <i>Gynecologic Oncology Reports</i> , 2022, 41, 100987.	0.6	3
44	Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors. <i>Translational Oncology</i> , 2022, 21, 101427.	3.7	1
45	Letter to the editor. <i>Medical Oncology</i> , 2010, 27, 569-569.	2.5	0
46	Chemotherapy Acute Infusion Reactions: A Qualitative Report of the Perspectives of Patients With Cancer. <i>American Journal of Hospice and Palliative Medicine</i> , 2018, 35, 1384-1389.	1.4	0
47	CHFR and Paclitaxel Sensitivity of Ovarian Cancer. <i>Cancers</i> , 2021, 13, 6043.	3.7	0